



## Cyxone presents at Aktiedagen the 27 January 2021

CEO Tara Heitner will present the latest updates in Cyxone on 27 January at 20.30 at the online event *Aktiedagen*. Information about the event together with the agenda is found on the [event's webpage](#). [Follow the presentation live here](#).

### Contact

Tara Heitner, CEO  
Tel: +46 70 781 88 08  
Email: [tara.heitner@cyxone.com](mailto:tara.heitner@cyxone.com)  
Adelgatan 21  
211 22 Malmö, Sweden

### About Cyxone

Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis and moderate Covid-19 infections. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is Mangold Fondkommission AB, +46 (0)8 503 015 50, [ca@mangold.se](mailto:ca@mangold.se). For more information, please visit [www.cyxone.com](http://www.cyxone.com)